QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Clinical trial NCT07733115 · RECRUITING
Trial details
- NCT number
- NCT07733115
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-20
- Primary completion
- 2028-06-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.